The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• KRAS mutations, particularly in codons 12 and 13, are prevalent in up to 30% of non-small cell lung cancer (NSCLC) cases.
• The advent of KRAS exon 2 p.G12C inhibitors like sotorasib and adagrasib presents novel therapeutic avenues for NSCLC treatment.
• Acquired resistance to KRAS exon 2 p.G12C inhibitors poses a significant clinical challenge, necessitating the exploration of alternative treatment strategies.

Purpose of the Study:

• To review current therapeutic strategies for KRAS-mutated NSCLC, focusing on KRAS exon 2 p.G12C inhibitors.
• To explore mechanisms of acquired resistance to KRAS exon 2 p.G12C inhibitors and potential combination therapies to overcome resistance.
• To discuss the role and efficacy of immune checkpoint inhibitors in the context of KRAS-mutated NSCLC.

Main Methods:

• Literature review of preclinical and clinical studies on KRAS exon 2 p.G12C inhibitors in NSCLC.
• Analysis of resistance mechanisms to KRAS exon 2 p.G12C inhibitors.
• Evaluation of combination therapy approaches, including targeting SHP2, SOS1, and downstream effectors.
• Review of the impact of co-occurring mutations on the efficacy of anti-PD-1/PD-L1 therapies in NSCLC.

Main Results:

• KRAS exon 2 p.G12C inhibitors have shown clinical promise, but acquired resistance is a growing concern.
• Combination strategies targeting SHP2, SOS1, or downstream KRAS effectors are emerging as effective approaches to overcome resistance.
• The efficacy of immune checkpoint inhibitors (anti-PD-1/PD-L1) in KRAS-mutated NSCLC is variable and influenced by co-mutations, suggesting a need for personalized treatment.

Conclusions:

• Targeted therapies and combination strategies are crucial for managing KRAS-mutated NSCLC, especially in the face of acquired resistance.
• Further research is needed to fully elucidate the efficacy of immune checkpoint inhibitors in this patient population.
• Personalized treatment approaches based on the comprehensive genetic profiling of NSCLC tumors are essential for optimizing patient outcomes.